In a July 30 research note, ROTH Capital Partners analyst Jonathan Aschoff provided an Oryzon Genomics S.A. (https://www.oryzon.com/) update, notable for significant clinical progress and a healthy ending cash balance.
Oryzon's stock has fourbagger potential, given that it is currently trading at about €3.53 per share and ROTH's target price on it is €15 per share.
Aschoff briefly addressed four developments related to Oryzon's clinical programs that occurred during Q2/21.
1) The Spain-based biopharma released updated results, in a poster presentation at the annual European Hematological Association meeting, from its ongoing Phase 2a ALICE trial of iadademstat plus azacitidine combination therapy for treatment-naďve acute myelogenous leukemia (AML) patients.
These data were positive, showing an 83% overall survival rate, which compares to 28% with azacitidine alone, the standard of care. Oryzon's study also showed a 67% rate of complete response/complete response with incomplete hematologic recovery; with standard of care treatment, it is 19%. A favorable safety profile was maintained throughout the study as well. Oryzon plans additional combination therapy trials in AML and solid tumors.
2) Oryzon highlighted vafidemstat's anti-inflammatory effect on hospitalized, severe COVID-19 patients, via an e-poster presentation of data from the Phase 2 ESCAPE trial. The bipharma presented these results at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases.
"A vafidemstat dose of 2.4 milligrams per day for five days durably and substantially occupied its target LSD1 and was well tolerated," Aschoff wrote.
3) Also regarding vafidemstat, the U.S. Food and Drug Administration approved the Phase 2b investigational new drug trial PORTICO, testing this drug in borderline personality disorder (BPD). The aim is to show vafidemstat can decrease agitation and aggression, for which there is not any current treatment, thereby helping BPD patients. The study will encompass 15–20 sites in the U.S. and Europe and about 156 patients. Enrollment already has started in Europe.
4) Spanish drug regulators approved Oryzon's clinical trial application for EVOLUTION, a Phase 2b study testing vafidemstat in schizophrenia. Recruitment is expected to commence in the next couple of months.
Finally, Aschoff reported that the takeaway from Oryzon's just released Q2/21 financials is that the company had a cash balance of $40.1 million at the quarter's end.
"That should fund operations into Q1/23, as per our projections," he added.
ROTH has a Buy rating on Oryzon.
[NLINSERT]Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ?????. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with ?????. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ?????, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
